High expectations are held for human-induced pluripotent stem cells (hiPSC) since they are established from autologous tissues thus overcoming the risk of allogeneic immune rejection when used in regenerative medicine. However, little is known regarding the cell-surface carbohydrate antigen profile of hiPSC compared with human embryonic stem cells (hESC). Here, glycosphingolipids were isolated from an adipocyte-derived hiPSC line, and hiPSC and hESC glycosphingolipids were compared by concurrent characterization by binding assays with carbohydrate-recognizing ligands and mass spectrometry. A high similarity between the nonacid glycosphingolipids of hiPSC and hESC was found. The nonacid glycosphingolipids P1 pentaosylceramide, x 2 pentaosylceramide and H type 1 heptaosylceramide, not previously described in human pluripotent stem cells (hPSC), were characterized in both hiPSC and hESC. The composition of acid glycosphingolipids differed, with increased levels of GM3 ganglioside, and reduced levels of GD1a/GD1b in hiPSC when compared with hESC. In addition, the hESC glycosphingolipids sulf-globopentaosylceramide and sialyl-globotetraosylceramide were lacking in hiPSC. Neural stem cells differentiating from hiPSC had a reduced expression of sialyl-lactotetra, whereas expression of the GD1a ganglioside was significantly increased. Thus, while sialyl-lactotetra is a marker of undifferentiated hPSC, GD1a is a novel marker of neural differentiation.
Introduction
Human embryonic stem cells (hESC) and human-induced pluripotent stem cells (hiPSC) hold great promise for biomedical research and regenerative medicine, due to their ability to self-renew indefinitely and to differentiate into all human cell types. Today, a great interest is directed toward hiPSC, since they, in contrary to hESC, can be patient derived and thereby may overcome the risk of allogeneic immune rejection after transplantation. However, it has repeatedly been questioned if the molecular and functional features of hiPSC are truly equivalent to hESC, and whether hiPSC have the same differentiation capacity as hESC. Several differences between hiPSC and hESC have been demonstrated, and it has been shown that hiPSC have molecular and behavioral features of the somatic tissue of origin ("somatic epigenetic memory"), that may negatively affect their potential to differentiate into certain cell types (reviewed in Robinton and Daley 2012) .
Cell-surface markers are used for definition and characterization of human pluripotent stem cells (hPSC). Several stem cell markers are based on cell-surface carbohydrate epitopes, such as the widely used glycosphingolipid globopentaosylceramide/stage-specific embryonic antigen (SSEA)-3 and sialyl-globopentaosylceramide/SSEA-4 (see Tables I and II for glycosphingolipid structures) , as well as the glycoprotein TRA 1-60/TRA 1-81 markers (Wright and Andrews 2009) . Recently, the blood group H type 1 epitope/SSEA-5 and the sialyllactotetra epitope were identified as novel hPSC carbohydrate markers (Tang et al. 2011; Barone et al. 2014) .
The first studies of hESC glycosphingolipids identified globo series glycosphingolipids (globotetraosylceramide, globopentaosylceramide/SSEA-3 and Globo H hexaosylceramide), type 1 core chain glycosphingolipids (lactotetraosylceramide and fucosyl-lactotetraosylceramide/H type 1 pentaosylceramide) and the gangliosides (GM3, GM1, GD1a or GD1b), sialyl-globopentaosylceramide/ SSEA-4 and disialyl-globopentaosylceramide (Liang et al. 2010 (Liang et al. , 2011 . The glycosphingolipid composition of hiPSC was recently characterized using immune techniques and mass spectrometry of crude lipid extracts, giving a similar glycosphingolipid profile (Ojima et al. 2015) . A comparison of the glycome, including glycosphingolipids, of hESC and hiPSC has also been reported (Fujitani et al. 2013) . However, in this study, the hiPSC and hESC preparations also contained glycosphingolipids derived from the mouse feeder cells, which complicate the interpretation of the results.
In our recent studies of nonacid and acid glycosphingolipids from two hESC lines (SA121 and SA181) cultivated in a serum and feeder cell-free system, the glycosphingolipids were isolated from relatively large amounts of cells (1 × 10 9 cells per cell line) (Barone et al. 2013 (Barone et al. , 2014 . This allowed a higher resolution of the hESC glycosphingolipids, and several nonacid glycosphingolipids not previously described in hPSC were identified, e.g. type 2 core chain glycosphingolipids (the H type 2 pentaosylceramide, the Le x pentaosylceramide and Le y hexaosylceramide), and also a blood group A type 1 hexaosylceramide. Novel hESC gangliosides (sialyl-lactotetraosylceramide and sialyl-globotetraosylceramide) and a number of sulfated glycosphingolipids (sulfatide, sulf-lactosylceramide and sulf-globopentaosylceramide) were also characterized. Furthermore, the sialyl-lactotetra sequence was identified as a novel marker of undifferentiated hPSC, having a high cell-surface expression on both hESC and hiPSC, which was rapidly downregulated upon differentiation into hepatocyte-like and cardiomyocyte-like cells.
In this study, we have isolated acid and nonacid glycosphingolipids from a hiPSC line derived from human adipocytes, again using 1 × 10 9 cells as a starting material, enabling the isolation of total acid and nonacid glycosphingolipid fractions, and further separation of these into subfractions. Structural determination was carried out with complementary techniques, including thin-layer chromatogram binding assays, and liquid chromatography/electrospray ionization mass spectrometry (LC-ESI/MS) of native glycosphingolipids and glycosphingolipid-derived oligosaccharides. In addition, the changes in glycosphingolipid expression upon neural differentiation were followed by immunofluorescence studies and flow cytometry.
Results

Isolation of total acid and nonacid glycosphingolipids from hiPSC
Isolation of acid and nonacid glycosphingolipids from the adipocyte-derived hiPSC line CI2-iPSC (1 × 10 9 cells) gave 6.5 mg of total acid and 5.4 mg of total nonacid glycosphingolipids. When analyzed by thin-layer chromatography and chemical staining, the total nonacid and total acid glycosphingolipids of hiPSC were very similar to the glycosphingolipids isolated from the hESC line SA181 ( Figure 1A and B). However, the band migrating in the triglycosylceramide region was more pronounced in the nonacid fraction of hiPSC, and there was also an increase in the compounds migrating in the pentaglycosylceramide region ( Figure 1A , lane 2).
Characterization of the nonacid glycosphingolipids of hiPSC
Part of the hiPSC total nonacid glycosphingolipid fraction was separated on an Iatrobeads column, in order to enrich the slow-migrating glycosphingolipids. Thereby, four glycosphingolipid-containing fractions were obtained, denoted fraction N1 (0.3 mg), fraction N2 (0.4 mg), fraction N3 (1.0 mg) and fraction N4 (0.9 mg), respectively ( Figure 1C , lanes 2-5).
Fraction N1
Fraction N1 was characterized as a mixture of glucosylceramide (Glcß1Cer) and galactosylceramide (Galß1Cer). This conclusion is based on the following observations: (I) On thin-layer chromatograms, fraction N1 migrated in the monoglycosylceramide region ( Figure 1C , lane 2).
(II) When analyzed by thin-layer chromatography on borateimpregnated silica gel plates, the major part of the compounds in N1 migrated as glucosylceramides (approximately 90%) and a minor part as galactosylceramides (approximately 10%) (not shown).
Fractions N2 and N3 Fraction N2 was a mixture of monohexosylceramides (glucosylceramide and galactosylceramide), dihexosylceramide and globotriaosylceramide, while fraction N3 contained globotriaosylceramide, globotetraosylceramide, lactotriaosylceramide, H type 1 pentaosylceramide, neolactotetraosylceramide and lactotetraosylceramide. This conclusion was based on the following properties:
(I) Thin-layer chromatography demonstrated that fraction N2 contained compounds migrating in the mono-, di-and triglycosylceramide regions ( Figure 1C , lane 3), and the major compounds of fraction N3 migrated as tri-and tetra-glycosylceramides ( Figure 1C , lane 4). (II) Galα4 Gal-binding P-fimbriated Escherichia coli bound to a compound migrating in the triglycosylceramide region of fraction N2, and to compounds in the tri-and tetra-glycosylceramide regions of fraction N3 ( Figure 2B , lanes 1 and 2), indicating the presence of globotriaosylceramide and globotetraosylceramide in these fractions. , and by comparison of retention times and MS 2 spectra of oligosaccharides from reference glycosphingolipids (Karlsson et al. 2010; Barone et al. 2013) , gave a tentative identification of the glycosphingolipidderived oligosaccharides. Thus, a globo trisaccharide (Galα4Ga lß4Glc) was identified in fraction N2, while fraction N3 had a globo trisaccharide, a lacto trisaccharide (GlcNAcß3Galß4Glc), a globo tetrasaccharide (GalNAcß3Galα4Galß4Glc), a lacto tetrasa ccharide (Galß3GlcNAcß3Galß4Glc), a neolacto tetrasaccharide (Galß4GlcNAcß3Galß4Glc) and an H type 1 pentasaccharide (Fu cα2Galß3GlcNAcß3Galß4Glc) (Supplementary data, Figure S3 ). The glycosphingolipids identified by MS 2 are summarized in Table I .
It should here be noted that the intensities of the peaks do not reflect the relative amounts of the glycosphingolipids in the samples since the endoglycoceramidase II from Rhodococcus sp. has restricted hydrolytic capacity, and globo-and ganglio-series glycosphingolipids are relatively resistant to this enzyme (Ito and Yamagata 1989 (I) Thin-layer chromatography showed that fraction N4 had compounds migrating in the tetraglycosylceramide region and below ( Figure 1C , lane 5). (II) Galα4 Gal-binding P-fimbriated E. coli and monoclonal antibodies directed against the blood group H type 1 epitope, the Le x epitope, the globopenta/SSEA-3 epitope and the Globo H epitope, all bound to compounds in fraction N4 ( Figure 2B -F, lane 3). These carbohydrate binding ligands also gave similar binding patterns in the nonacid glycosphingolipid fraction of the hESC line SA181 ( Figure 2B -F, lane 4), except the anti-Le x antibody that gave a more pronounced binding to the hESC fraction. (III) The oligosaccharides obtained by hydrolysis with endoglycoceramidase of both fraction N4 from the hiPSC line CI2 and fraction 181:IV from hESC line SA181 (Barone et al. 2013) were analyzed by LC-ESI/MS on the same graphite column. The base peak chromatograms obtained were very similar ( Figure 3A and B Figure S4 ), and the oligosaccharides thereby identified are summarized in Table I . The only difference detected was the A type 1 hexasaccharide (m/z 1055), which was identified in the hESC fraction, but not present in the hiPSC fraction. This is in agreement with the ABO genotyping, where the hiPSC line CI2 was found to be of blood group O genotype (not shown). A-type fragments are diagnostic for carbohydrates substituted at C-4 (Chai et al. 2001; Robbe et al. 2004; Karlsson et al. 2010) , and here the 0,2 A 4 fragment ion demonstrated a 4-substitution of the innermost HexNAc, i.e. a type 2 core chain. Thus, the spectral features demonstrated a heptasaccharide with terminal Le x determinant and type 2 core chain, most likely derived from a Le x heptaosylceramide (Galß4 (Fucα3)GlcNAcß3Galß4GlcNAcß3Galß4Glcß1Cer), as previously described for hESC (Barone et al. 2013 ).
The MS 2 spectrum of the ion at m/z 868 ( Figure 4D A 4 -H 2 O ion at m/z 790 were derived from cross-ring cleavage of the 4-substituted Glc of the lactose unit at the reducing end. Thus, a pentasaccharide with HexHex-4HexNAc-Hex-4Hex sequence was identified, most likely a Gal-Galß4GlcNAcß3Galß4Glc saccharide, as the Galα3 xenoantigen (Galα3Galß4GlcNAcβ3 Galβ4Glc) or the P1 pentasaccharide (Galα4Galβ4GlcNAcβ3Galβ4Glc). No further information about the terminal Hex-Hex sequence was obtained by MS 3 . However, no binding of the Galα3 binding IB4 lectin from Griffonia simplicifolia to the pentaglycosylceramide region of hiPSC or hESC nonacid glycosphingolipids was obtained (not shown), and since the alpha1,3-galactosyltransferase is not expressed in humans due to frameshift mutations (Larsen et al. 1990 ), this pentasaccharide was tentatively identified as derived from the P1 pentaosylceramide (Galα4Galβ4G lcNAcβ3Galβ4Glcβ1Cer). The MS 2 spectrum of the ion at m/z 909 ( Figure A 5 -H 2 O ion at m/z 831 were derived from the 4-substituted Glc of the lactose unit at the reducing end. Thus, a HexNAc-Hex-4HexNAc-Hex-4Hex pentasaccharide was identified. This MS 2 spectrum was very similar to the MS 2 spectrum of the x 2 pentasaccharide (Westman et al. 2015) , which indicated that this pentasaccharide was derived from the x 2 pentaosylceramide (GalNAcβ3Galβ4G lcNAcβ3Galβ4Glcβ1Cer). Finally, a oligosaccharide with Fuc-Hex-HexNAc-Hex-HexNAcHex-Hex sequence was identified by MS 2 of the ion at m/z 1217 eluting at 25.1-25.8 min ( Figure 4F ). This was deduced from the -5, Galß4(Fucα3)GlcNAcß3Galß4Glc; GbH, Fucα2Galß3GalNAcß3Galα4Galß4Glc; A6-1, GalNAcα3(Fucα2) Galß3GlcNAcß3Galß4Glc; Le y -6, Fucα2Galß4(Fucα3)GlcNAcß3Galß4Glc; H5-1, Fucα2Galß4GlcNAcß3Galß4Glc; nLc4, Galß4GlcNAcß3Galß4Glc; Lc4, Galß3GlcN Acß3Galß4Glc; H5-2, Fucα2Galß4GlcNAcß3Galß4Glc; H7-1, Fucα2Galß4GlcNAcß3Galß4GlcNAcß3Galß4Glc; Lc6, Galß3GlcNAcß3Galß3/4GlcNAcß3Galß4Glc; nLc6, Galß4GlcNAcß3Galß4GlcNAcß3Galß4Glc.
C-type fragment ion series (C 3 at m/z 528, C 4 at m/z 690, C 5 at m/z 893 and C 6 at m/z 1055), along with the C 2 ion at m/z 325 obtained by MS 3 of the ion at m/z 690 ( Figure 4G ). No cross-ring 0,2 A-type fragments were found. Taken together, this suggested a Fuc-Hex3HexNAc-Hex-3HexNAc-Hex-Hex sequence, most likely derived from a H type 1 heptaosylceramide (Fucα2Galβ3GlcNAcβ3Galβ4G lcNAcβ3Galβ4Glcβ1Cer). Re-analyses of the oligosaccharides derived from fraction 181:IV from the hESC line SA181 demonstrated minor peaks at m/z 868, 909 and 1217 also in the hESC sample ( Figure 4A ), and the P1 pentasaccharide, the x 2 pentasaccharide and the H type 1 heptasaccharide were tentatively identified by MS 2 also in this case.
Taken together, the chromatogram binding assays and the results from LC-ESI/MS show that there is a high similarity between the nonacid glycosphingolipids of hiPSC and hESC.
Characterization of the acid glycosphingolipids of hiPSC
The total acid glycosphingolipid fraction from adipocyte-derived hiPSC was separated on an Iatrobeads column, giving two subfractions denoted fraction A1 (0.3 mg) and fraction A2 (1.0 mg). Fraction A1 contained mainly compounds migrating in the sulfatide region on thin-layer chromatograms and was not stained by resorcinol ( Figure 1D and E, lane 1), whereas more slow-migrating resorcinolpositive compounds were present in fraction A2 ( Figure 1D and E, lane 2). The presence of the SO 3 -3Galß-terminated glycosphingolipids sulfatide and sulfated lactosylceramide in fraction A1 was indicated by binding of the Sulph-1 antibody to two sets of double bands migrating just above and below the level of reference sulfatide (not shown). Monoclonal antibodies directed against the sialyl-lactotetra and sialylglobopenta/SSEA-4 epitopes gave a distinct binding in fraction A2 ( Figure 5C and D, lane 2), suggesting the presence of sialyllactotetraosylceramide and sialyl-globopentaosylceramide, respectively. Binding of monoclonal antibodies directed against sialyl-lactotetra and sialyl-globopenta/SSEA-4 to the acid glycosphingolipids of hESC has been demonstrated previously (Barone et al. 2014) . No binding of monoclonal antibodies against the sialyl-neolactotetra epitope or the GD1a ganglioside to the hiPSC fractions A1 or A2 was obtained.
The Figure S7 ). The acid glycosphingolipids characterized are summarized in Table II . All these acid glycosphingolipids, except the minor GT1a/GT1b gangliosides, have previously been identified in hESC (Barone et al. 2014 ).
Comparison of the base peak chromatograms from hESC fraction 181 C and hiPSC fraction A2 shows that the molecular ion at m/z 1151, identifying the GM3 ganglioside, is much more intense in hiPSC (Figure 6 ). Furthermore, some molecular ions in the hESC sample ( Figure 6A and C) were absent in the sample from hiPSC ( Figure 6B 18.9 min, identifying sialyl-globoside, in the sample from hiPSC. The latter two molecular ions could not be found by search for selected ions. Thus, LC-ESI/MS indicated that hiPSC had increased levels of the GM3 ganglioside and reduced levels of GD1a/GD1b when compared with hESC, and the hESC glycosphingolipids sulfglobopentaosylceramide and sialyl-globotetraosylceramide were not detected in hiPSC.
Changes of carbohydrate expression during neural differentiation
Immunofluorescence staining was first used for evaluation of the presence of carbohydrate determinants in permeabilized undifferentiated hiPSC glycosphingolipids and glycoproteins. In addition to a distinct nuclear staining for the pluripotency marker Oct4 (not shown), the undifferentiated hiPSC showed staining when assayed for sialyllactotetra immunoreactivity (Supplementary data, Figure S8H ). Sialyl-globotetra/SSEA-4 and GD1a immunoreactivity was also obtained (Supplementary data, Figure S8B and E).
Next, the expression of carbohydrate epitopes on neural stem cell glycosphingolipids and glycoproteins after 23 days differentiation was investigated by immunofluorescence and flow cytometry. The neural characteristics of the differentiated cells was confirmed by the expression of the neural markers MAP2ab and Otx2 ( Figure 7B and C), whereas expression of the pluripotency marker Oct4 (Datta et al. 2013) was not found ( Figure 7G) . A loss of sialyl-lactotetra upon differentiation was observed ( Figure 7M ), while on the other hand the GD1a ganglioside ( Figure 7F ) and the Le x determinant ( Figure 7J) were expressed on the cell surface after 23 days differentiation. Flow-cytometry analyses also showed a reduction of the sialyllactotetra-positive cells from 98% at day 0 to 37% at day 23 of neural differentiation, and a coherent reduction in fluorescence intensity ( Figure 8A and B) . In contrast, the presence of the GD1a ganglioside increased during neural stem cells (NSC) differentiation, since no cell-surface expression was found on the undifferentiated hiPSC, whereas almost all (96%) of 23-day differentiated NSC were positive ( Figure 8CD ).
The expression of the Le x determinant also increased from 61%
at day 0 to 98% at day 23 of differentiation ( Figure 8E and F), while there was a reduction in the expression of the Le y determinant from 98% at day 0 to 70% at day 23 ( Figure 8G and H).
Discussion
Human embryonic and induced pluripotent stem cells have a huge potential in regenerative medicine, and several studies using hESC-or hiPSC-based cellular therapies for treatment of diseases in human subjects are now underway (reviewed in Angelos and Kaufman 2015 and Ilic et al. 2015) . This rapid development necessitates a parallel rapid progress in stem cell quality control, both of undifferentiated cells and cells that have undergone derivation and expansion. Carbohydrate markers may be important tools in defining these aspects, and it is critical to extend the range of markers that can be used to confirm the pluripotency, quality, identity and safety of pluripotent cell lines. In a number of recent studies, the glycosphingolipids of hPSC have been characterized using immune techniques and mass spectrometry of crude lipid extracts (Liang et al. 2010 (Liang et al. , 2011 Fujitani et al. 2013; Ojima et al. 2015) . This approach gives the identity of the major hPSC glycosphingolipids, while minor compounds e.g. type 2 chain glycosphingolipids are not detected. Our detailed characterization of the hiPSC glycosphingolipids supports and extends the study of Ojima et al. (2015) . Thus, we have comprehensively profiled the glycosphingolipids of hiPSC in parallel with hESC glycosphingolipids. The two types of hPSC were both cultured in a feeder cell and serum-free system, albeit at different time points. The relatively large amount of starting material (1 × 10 9 cells) allowed isolation of total acid and nonacid glycosphingolipid fractions, and even separation of the total glycosphingolipid fractions into subfractions, and an extended structural characterization combining LC-ESI/MS and binding assays with a battery of carbohydrate binding ligands. The majority of the glycosphingolipids identified in this study were common between hESC and hiPSC, and the profile of nonacid glycosphingolipids was almost identical. The only difference detected was the presence of the A type 1 hexaosylceramide in the nonacid glycosphingolipid fraction from hESC of blood group A 1 genotype. Blood group A glycosphingolipids were not found in the hiPSC fraction, in agreement with the typing of the hiPSC line CI2 as having blood group O.
However, the composition of acid glycosphingolipids in the two types of hPSC differed, with increased levels of GM3 ganglioside, and reduced levels of GD1a/GD1b in hiPSC when compared with hESC. In addition, sulf-globopentaosylceramide and sialylglobotetraosylceramide were uniquely observed in hESC. Consistent with our findings, the GD1a/GD1b gangliosides were not detected in hIPSC in the study by Ojima et al. (2015) .
The sialyl-lactotetra epitope was recently identified as a novel marker of hPSC (Barone et al. 2014 ). Here, sialyl-lactotetraosylceramide was characterized in hiPSC by a combination of mass spectrometry and binding of antisialyl-lactotetra antibodies. However, this ganglioside was not identified in the study of hiPSC glycosphingolipids by Ojima et al. (2015) . Instead the presence of the GM1 ganglioside was reported. Sialyl-lactotetraosylceramide and the GM1 ganglioside have the same composition (one NeuAc, one HexNAc and three Hex), and the reported series of fragment ions obtained by MS 2 had no Y 2 α ion demonstrating that the sialic acid is linked to the Gal of the lactose unit at the reducing end as in the GM1 ganglioside (Ojima et al. 2015) . Indeed, this fragment ion series is also compatible with a linear carbohydrate sequence as in sialyl-lactotetraosylceramide. Furthermore, when we tested the binding of cholera toxin B-subunits to the acid glycosphingolipids of hiPSC and hESC in the chromatogram binding assay, these GM1-binding B-subunits (Holmgren 1973) failed to bind. Therefore, the GM1 ganglioside identified in the study by Ojima et al. (2015) may have been sialyl-lactotetraosylceramide. The P1 and x 2 glycosphingolipids, and also the H type 1 heptaosylceramide, were here first characterized among the nonacid glycosphingolipids of hiPSC. However, by a directed search these three minor compounds were also found among the nonacid glycosphingolipids of hESC, and thus these three compounds may be added to the list of minor glycosphingolipids of hPSC.
Glycosphingolipids with terminal Le x sequence were characterized in both hiPSC and hESC. The presence of Le x sequences in undifferentiated hPSC is a somewhat controversial and confusing issue. The confusion is mainly caused by the marketing of the SSEA-1 defining antibody MC480 as an antibody specific for the Le x determinant as well as a differentiation marker. The MC480 antibody does not bind to undifferentiated hPSC (Thomson et al. 1998; Henderson et al. 2002) , and since commercial sources often state that the MC480 antibody is specific for the Le x determinant, this may lead to the interpretation that the Le x sequence is absent from undifferentiated hPSC. The reactivity of MC480 antibody is however restricted to the Le x epitope presented on long type 2 core chains (Gooi et al. 1981; Kannagi et al. 1982) . The Le x determinant has been characterized in hESC N-glycans (Satomaa et al. 2009) , and the complex glycosphingolipids of both hiPSC and hESC contained penta-and heptaglycosylceramides with terminal Le x determinants which are recognized by other anti-Le x antibodies. Cell-surface expression of the Le x determinant on hESC and hiPSC is also readily detected when using the anti-Le x antibody P12 in flow cytometry.
Identification of glycosphingolipids in hPSC may contribute to the understanding of their role in maintenance, proliferation and differentiation. In addition, such carbohydrate determinants may be used as markers for isolation of homogenous cell populations. The sialyl-lactotetra epitope expression was rapidly reduced upon differentiation of hESC into hepatocyte-like cells and cardiomyocyte-like cells, and not detectable 14 days after induction (Barone et al. 2014 ). The expression of glycan determinants on hiPSC after differentiation into NSC was now evaluated by immunofluorescence and flow cytometry, demonstrating that sialyl-lactotetra determinant expression was reduced significantly from day 0 to day 23 after induction of differentiation. In contrast, expression of the GD1a ganglioside and the Le x determinant was upregulated, and cell-surface GD1a and Le x were detected on virtually all NSC after 23 days differentiation. Thus, sialyl-lactotetra is downregulated under ectodermal, endodermal and mesodermal differentiation, demonstrating that sialyl-lactotetra expression represents the undifferentiated state of the cells and may be used for quality control of hPSC-derived cell products.
Anti-Le x antibodies are often used for labeling and isolation of NSC derived from hPSC (Hennen and Faissner 2012) . However, the Galß3GalNAcß3Galα4Galß4Glcß1Cer; S-Gb4, Neu5Acα3GalNAcß3Galα4Galß4Glcß1Cer; S-L4, Neu5Acα3Galß3GlcNAcß3Galß4Glcß1Cer; S-Gb5, Neu5A cα3Galß3GalNAcß3Galα4Galß4Glcß1Cer; GD1a, Neu5Acα3 Galβ3GalNAcβ4(Neu5Acα3)Galβ4Glcβ1Cer; GD1b, Galβ3GalNAcβ4(Neu5Acα8Neu5Acα3)Galβ4Glcβ1Cer; SO 3 -LC, SO 3 -Galß4Glcß1Cer; S 2 -Gb5, Neu5Acα3 Galβ3(Neu5Acα6)GalNAcβ3 Galα4 Galβ4Glcβ1Cer; GM3, Neu5Acα3Galß4Glcß1Cer. NL represents a measure of absolute spectral counts for the most abundant peak (100% on the y-axis). This figure is available in black and white in print and in colour at Glycobiology online. Le x determinant is to some extent also expressed by the cells in the undifferentiated state. Our present data demonstrate that the GD1a ganglioside is not found on undifferentiated hiPSC, but upregulated by neural differentiation and present on virtually all NSC after 23 days. This suggests that anti-GD1a antibodies might be useful novel tools for NSC isolation and characterization.
Materials and methods hiPSC lines and culture conditions
The hiPSC lines CI2-iPSC and CI3-iPSC were derived from human adipocytes, and characterized by Takara Bio Europe AB (Gothenburg, Sweden). The fibroblast-derived Cellartis DEF-hiPSC™ ChiPSC4 line was obtained from Takara Bio Europe AB. The cell lines were cultured under feeder-free conditions in Cellartis DEF-CS™ medium (Takara Bio Europe AB) at 37°C in a humidified atmosphere of 5% CO 2 in air. Cellartis DEF-CS™ medium is a feeder cell-free system that is free from human-and animal-derived compounds.
Directed differentiation of hiPSC
The CI2-iPSCs were plated on COAT1-coated 12-well plates (Takara Bio Europe AB) in feeder-free conditioned Cellartis DEF-CS™ medium, and cultured until confluent. Neural induction was initiated by changing the culture medium to 1:1 mixture of N2 media (DMEM/F12 GlutaMAX (Life Technologies/Invitrogen, Carlsbad, CA), N2 supplement (Life Technologies), 5 mg/mL insulin (Sigma-Aldrich Saint Louis, MO), 1 mM Ultra glutamin (Lonza, Basel, Switzerland), 100 mM nonessential amino acids (Gibco), 100 mM 2-mercaptoethanol (Thermo Fisher Scientific, Waltham, MA), 50 U/mL penicillin and streptomycin (Lonza)), and B27 media (Neurobasal (Life Technologies), B27 without vitamin A (Life Technologies), 2 mM Ultra glutamine, 50 U/mL penicillin and streptomycin (Lonza)) supplemented with 1 mM Dorsomorphin (Tocris Bioscience, Bristol, UK) and 10 mM SB431542 (Tocris Bioscience). This neural induction medium was replaced every day for 10 days, i.e. until a uniform neuroepithelial sheet was observed. Neuroepithelial cells were collected by dissociation with Dispase (Life Technologies), and aggregates were replated on laminin-coated plates and maintained in neural maintenance medium (NSC medium; as above but without Dorsomorphin and SB431542). Upon appearance of rosette structures, NSC were expanded by supplementing the medium with 20 ng/mL fibroblast growth factor 2 (FGF-2) (Invitrogen). After further 4 days culture, FGF-2 was withdrawn and cultures were passaged using Accutase (Millipore, Billerica, MA), and maintained in neural maintenance medium, until frozen at day 23 post initiation of neural induction.
Isolation of glycosphingolipids from hiPSC
Acid and nonacid glycosphingolipids were isolated from the hiPSC line CI2-iPSC, essentially as described (Barone et al. 2013 (Barone et al. , 2014 . (A and B) , the GD1a ganglioside (C and D), the Le x determinant (E and F) and the Le y determinant (G and H), was evaluated at days 0 and 23 after induction of differentiation the hiPSC line CI2 into neural stem cells. The positive expression was described as the level of fluorescence greater than 99% of the corresponding control sample (stained only with secondary antibody or isotype control). See Supplementary data, Figure S9 for backgating procedure. This figure is available in black and white in print and in colour at Glycobiology online.
The cells (1 × 10 9 cells) were lyophilized, and thereafter extracted in two steps in a Soxhlet apparatus with chloroform and methanol (2:1 and 1:9, by volume, respectively). The material thereby obtained was subjected to mild alkaline hydrolysis and dialysis. The major nonpolar lipids were removed by separation on a silicic acid column. Acid and nonacid glycosphingolipid fractions were then separated by DEAE-cellulose column chromatography. In order to separate the nonacid glycosphingolipids from alkali-stable phospholipids, the polar lipid fraction was acetylated and separated on a second silicic acid column, followed by deacetylation and dialysis. Approximately 6.5 mg of total acid and 5.4 mg of total nonacid glycosphingolipids were thereby obtained. After initial chromatogram binding assays and mass spectrometry, the remaining total nonacid glycosphingolipids were separated on a 0.5-g Iatrobeads (Iatrobeads 6RS-8060; Iatron Laboratories, Tokyo, Japan) column, eluted with increasing amounts of methanol in chloroform, to remove remaining nonglycosphingolipid material and to separate the glycosphingolipids according to their number of carbohydrate residues. Four subfractions were collected and denoted fraction N1 (0.3 mg), fraction N2 (0.4 mg), fraction N3 (1.0 mg) and fraction N4 (0.9 mg). The total acid glycosphingolipids were also separated on a 0.5-g Iatrobeads column, eluted with increasing amounts of methanol in chloroform. This gave two subfractions denoted fraction A1 (0.3 mg) and fraction A2 (1.0 mg). The acid and nonacid subfractions were characterized by antibody binding and mass spectrometry, as detailed below.
Reference glycosphingolipids
Total acid and nonacid glycosphingolipid fractions and subfractions from the hESC line SA181 were isolated as described (Barone et al. 2013 (Barone et al. , 2014 . Reference total acid and nonacid glycosphingolipid fractions from human erythrocytes, calf brain, and human lung cancer liver metastasis were isolated by standard methods (Karlsson 1987) . The pure reference glycosphingolipids were obtained by repeated chromatographies on silicic acid columns, and by high performance liquid chromatography, and characterized by mass spectrometry and proton NMR spectroscopy, as described (Karlsson 1987) . Glucosylceramide from human Gaucher's spleen and galactosylceramide from bovine brain were purchased from Sigma.
Thin-layer chromatography
Aluminum-or glass-backed silica gel 60 high performance thin-layer chromatography plates (Merck, Darmstadt, Germany) were used for thin-layer chromatography, and eluted with chloroform/methanol/ water (60:35:8, by volume) as solvent system. The different glycosphingolipids were applied to the plates in quantities of 3 µg of pure glycosphingolipids and 10-40 µg of glycosphingolipid mixtures. Glycosphingolipids were detected by the anisaldehyde reagent (Waldi 1962) or the resorcinol reagent (Svennerholm and Fredman 1980) . Borate-impregnated plates (Karlsson et al. 1973) were prepared by spraying glass-backed silica gel 60 high performance thin-layer chromatography plates with 1% (w/v) aqueous sodium tetraborate, followed by activation for 30 min at 120°C. Chromatography on the borate-impreganated plates was done using chloroform/methanol/water (100:30:4, by volume) as solvent system. 
Chromatogram binding assays
The lectins and monoclonal antibodies used in the chromatogram binding assays are given in Table III . Binding of monoclonal antibodies to glycosphingolipids on thin-layer chromatograms was performed as described (Barone et al. 2013 (Barone et al. , 2014 . Chromatograms with separated glycosphingolipids were dipped for 1 min in diethylether/nhexane (1:5, by volume) containing 0.5% (w/v) polyisobutylmethacrylate (Aldrich Chem. Comp. Inc., Milwaukee, WI). After drying, the chromatograms were soaked in phosphate-buffered saline (PBS) containing 2% bovine serum albumin and 0.1% NaN 3 (Solution A), for 2 h at room temperature. Suspensions of monoclonal antibodies (the dilution used for each antibody is given in Table III ) in Sol. A were gently sprinkled over the chromatograms, followed by incubation for 2 h at room temperature. After washing with PBS followed a second 2 h incubation with coli strain HB101/pPIL291-15, were done as described (Teneberg et al. 1994; Roche et al. 2007 ).
LC-ESI/MS of native glycosphingolipids
Aliquots of glycosphingolipid fractions were dissolved in methanol: acetonitrile in proportion 75:25 (by volume) and separated on a 200 × 0.250 mm column, packed in-house with 5 µm polyamine II particles (YMC Europe GmbH, Dinslaken, Germany). An autosampler, HTC-PAL (CTC Analytics AG, Zwingen, Switzerland) equipped with a cheminert valve (0.25 mm bore) and a 2-µL loop, was used for sample injection. An Agilent 1100 binary pump (Agilent Technologies, Palo Alto, CA) delivered a flow of 250 µL/min, which was splitted down in an 1/16″ microvolume-T (0.15 mm bore) (Vici AG International, Schenkon, Switzerland) by a 50 cm x 50 µm i.d. fused silica capillary before the injector of the autosampler, allowing approximately 2-3 µL/ min through the column. Samples were eluted with an aqueous gradient (A: 100% acetonitrile to B: 10 mM ammonium bicarbonate). The gradient (0-50% B) was eluted for 40 min, followed by a wash step with 100% B, and equilibration of the column for 20 min. The samples were analyzed in negative ion mode on a LTQ linear quadropole ion trap mass spectrometer (Thermo Electron, San José, CA), with an IonMax standard ESI source equipped with a stainless steel needle kept at -3.5 kV. Compressed air was used as nebulizer gas. The heated capillary was kept at 270°C, and the capillary voltage was -50 kV. Full scan (m/z 500-1800, two microscans, maximum 100 ms, target value of 30,000) was performed, followed by data-dependent MS 2 scans (two microscans, maximum 100 ms, target value of 10,000) with normalized collision energy of 35%, isolation window of 2.5 units, activation q of 0.25 and activation time of 30 ms. The threshold for MS 2 was set to 500 counts.
Data acquisition and processing were conducted with Xcalibur software (Version 2.0.7). Manual assignment of glycosphingolipid sequences was done with the assistance of the Glycoworkbench tool (Version 2.1), and by comparison of retention times and MS 2 spectra of reference glycosphingolipids.
Endoglycoceramidase digestion and LC-ESI/MS
Endoglycoceramidase II from Rhodococcus spp. (Takara Bio Europe S.A., Gennevilliers, France) was used for hydrolysis of the nonacid glycosphingolipids. The glycosphingolipids (50 µg) were resuspended in 100 µL 0.05 M sodium acetate buffer, pH 5.0, containing 120 µg sodium cholate, and sonicated briefly. Thereafter, 1 mU of enzyme was added, and the mixture was incubated at 37°C for 48 h. The reaction was stopped by addition of chloroform/methanol/water to the final proportions 8:4:3 (by volume). The oligosaccharide-containing upper phase thus obtained was separated from detergent on a SepPak QMA cartridge (Waters). The eluant containing the oligosaccharides was dried under nitrogen and under vacuum. The glycosphingolipid-derived oligosaccharides were resuspended in 50 µL of water and analyzed by LC-ESI/MS as described (Karlsson et al. 2010) . The oligosaccharides were separated on a column (200 × 0.180 mm) packed in-house with 5 µm porous graphite particles (Hypercarb, Thermo-Hypersil, Runcorn, UK). An autosampler, HTC-PAL (CTC Analytics AG) equipped with a cheminert valve (0.25 mm bore) and a 2-µL loop, was used for sample injection. An Agilent 1100 binary pump (Agilent Technologies) delivered a flow of 250 µL/min, which was splitted down in an 1/16″ microvolume-T (0.15 mm bore) (Vici AG International) by a 50 cm x 50 µm i.d. fused silica capillary before the injector of the autosampler, allowing approximately 2-3 µL/min through the column. The oligosaccharides (3 µL) were injected onto the column and eluted with an acetonitrile gradient (A: 10 mM ammonium bicarbonate; B: 10 mM ammonium bicarbonate in 80% acetonitrile). The gradient (0-45% B) was eluted for 46 min, followed by a wash step with 100% B, and equilibration of the column for 24 min. A 30 cm x 50 µm i.d. fused silica capillary was used as transfer line to the ion source.
The saccharides were analyzed in negative ion mode on an LTQ linear quadrupole ion trap mass spectrometer (Thermo Electron). The IonMax standard ESI source on the LTQ mass spectrometer was equipped with a stainless steel needle kept at -3.5 kV. Compressed air was used as nebulizer gas. The heated capillary was kept at 270°C, and the capillary voltage was -50 kV. Full scan (m/z 380-2000, 2 microscans, maximum 100 ms, target value of 30,000) was performed, followed by data-dependent MS 2 scans of the three most abundant ions in each scan (2 microscans, maximum 100 ms, target value of 10,000). The threshold for MS 2 was set to 500 counts. Normalized collision energy was 35%, and an isolation window of 3 units, an activation q of 0.25 and an activation time of 30 ms were used. Data acquisition and processing were conducted with Xcalibur software (Version 2.0.7). Manual assignment of glycan sequences was done on the basis of knowledge of mammalian biosynthetic pathways, with the assistance of the Glycoworkbench tool (Version 2.1), and by comparison of retention times and MS 2 spectra of oligosaccharides from reference glycosphingolipids (Karlsson et al. 2010 ).
Immunofluorescence
For immunofluorescence, pluripotent or differentiated hiPSC were dissociated with TrypleLE TM Select (Invitrogen) and Accutase, respectively. After counting the cells, 5.0 × 10 6 cells were replated onto 8-well chamber slides coated with laminin 521 (Biolamina, Sundbyberg, Sweden), and cultured overnight in Cellartis DEF-CS™ medium or neural maintenance medium. Cells were fixated with 4.0% paraformaldehyde/PBS for 20 min, washed, permeabilized with 0.25% Triton X-100/PBS, pH 7.3 (PBS) for 10 min, and thereafter blocked in 0.1% Tween 20/0.3 M glycine/10% normal donkey or goat serum/PBS for 1 h. The primary antibodies used are given in Table III . Primary and secondary antibodies (Alexa Fluor 488-conjugated donkey antimouse IgG, Alexa Fluor 555-conjugated donkey antirabbit IgG, Alexa Fluor 488-conjugated goat antimouse IgM and Alexa Fluor 555-conjugated goat antirabbit IgM; 1:1000, Life Technologies) were diluted in 0.1% Tween 20/0.3 M glycine/10% normal donkey or goat serum/PBS and incubated for 2 and 1 h, respectively, each followed by washes in 0.1% Tween 20/PBS. Nuclei were counterstained with Hoechst. Slides were mounted and analyzed on Nikon Eclipse Ni-E automated upright microscope equipped with Orca Flash 4.0 camera (Hamamatsu Photonics, Shizuoka, Japan), using CFI S Fluor ×40/1.30 Oil or CFI Plan Fluor ×60 (Nikon Corp., Tokyo, Japan) objective. 
Flow cytometry
Single-color fluorescence was used to phenotypically characterize the cell-surface antigens of the different cell lines. The hiPSC and NSC were dissociated from the plates using TrypleSelect or Accutase, respectively, and washed with PBS. After resuspending in Cellartis DEF-CS™ or neural maintenance medium, the cells were passed through a 40-m cell stainer (Becton Dickinson, Stockholm, Sweden) to separate nondissociated clumps. Approximately 2 × 10 5 cells were distributed in each tube. The suspensions were centrifugated for 5 min at 260 × g (Becton Dickinson-microsystem), and the supernatants extracted by Vacusafe aspiration system (Becton Dickinson). The cell pellets were incubated with 25 L primary antibodies (the primary antibodies, and the dilutions, used are given in Table III) or corresponding isotype controls for 30 min at 4°C, and subsequently washed twice in cold PBS-FCS (PBS with 2% fetal calf serum) solution, following the same procedure as earlier described. Cells stained with primary antibodies were thereafter incubated with corresponding FITC-conjugated secondary antibodies for 30 min at 4°C under the same conditions. Following two washing cycles, the stained cells were resuspended in 200 µL PBS and analyzed using a FACSCalibur TM flow cytometer (Becton Dickinson).
Fluorescence signals from 10,000 to 20,000 cells were acquired using CellQuest TM software, and analyzed by the FlowJo (v10.1.r5) software.
Dead cells and debris were excluded by using a propidium iodide exclusion method (0.5 µg/mL; Sigma Aldrich), and by adjusting forward and side light scatter gates.
ABO genotyping
ABO typing of DNA extracted from the hiPSC line CI2 was achieved by a modified PCR-SSP method according to a protocol from Downing and Darke (2003) , using Taq PCR Master Mix Kit (QIAGEN, Hilden, Germany) on a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA). Primers were bought from Scandinavian Gene Synthesis (Köping, Sweden) and the gels were analyzed using a LumiBIS detection system (DNR Bio-Imaging Systems Ltd., Neve Yamin, Israel).
Supplementary data
Supplementary data for this article is available at Glycobiology online.
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